• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Rockwell Medical Inc. (DE) (Amendment)

    6/23/22 4:57:53 PM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RMTI alert in real time by email
    SC 13D/A 1 ea161940-13da16richmond_rock.htm AMENDMENT NO. 16 TO SCHEDULE 13D

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13D

    (Rule 13d-101)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO

    § 240.13d-2(a)

     

    (Amendment No. 16)1

     

    Rockwell Medical, Inc.

    (Name of Issuer)

     

    Common Stock, par value 0.0001 per share

    (Title of Class of Securities)

     

    774374102

    (CUSIP Number)

     

    DAVID S. RICHMONd

    richmond brothers, Inc.

    3568 Wildwood Avenue

    Jackson, Michigan 49202

    (517) 435-4040

     

    GUY P. LANDER

    CARTER LEDYARD & MILBURN LLP

    2 WALL STREET, NEW YORK, NY 10005

    212-732-3200

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

     

    May 30, 2022

    (Date of Event Which Requires Filing of This Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box  ☐.

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7 for other parties to whom copies are to be sent.

     

    1The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 774374102

      

    1  

    NAME OF REPORTING PERSON

     

    Richmond Brothers, Inc.

     
    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

    (a)  ☒

    (b)  ☐

    3  

    SEC USE ONLY

     

     

     
    4  

    SOURCE OF FUNDS

     

    OO

     
    5  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)

     

    ☐
    6  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    MICHIGAN

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

      7  

    SOLE VOTING POWER

     

    5,570

      8  

    SHARED VOTING POWER

     

    - 0 -

      9  

    SOLE DISPOSITIVE VOTING POWER

     

    5,570

      10  

    SHARED DISPOSITIVE POWER

            

    589,505

    11  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    595,075

     
    12  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    ☐
    13  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    6.3%

     
    14  

    TYPE OF REPORTING PERSON

     

    IA, CO

     

     

    2

     

     

    CUSIP No. 774374102

     

    1  

    NAME OF REPORTING PERSON

     

    RBI Private Investment I, LLC

     
    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

    (a)  ☒

    (b)  ☐

    3  

    SEC USE ONLY

     

     

     
    4  

    SOURCE OF FUNDS

     

    WC

     
    5  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)

     

    ☐
    6  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    DELAWARE

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

      7  

    SOLE VOTING POWER

     

    5,894

      8  

    SHARED VOTING POWER

     

    - 0 -

      9  

    SOLE DISPOSITIVE VOTING POWER

     

    5,894

      10  

    SHARED DISPOSITIVE POWER

            

    - 0 -

    11  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    5,894

     
    12  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    ☐
    13  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    Less than 1%

     
    14  

    TYPE OF REPORTING PERSON

     

    OO

     

     

    3

     

     

    CUSIP No. 774374102

     

    1  

    NAME OF REPORTING PERSON

     

    RBI Private Investment II, LLC

     
    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

    (a)  ☒

    (b)  ☐

    3  

    SEC USE ONLY

     

     

     
    4  

    SOURCE OF FUNDS

     

    WC

     
    5  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)

     

    ☐
    6  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    DELAWARE

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

      7  

    SOLE VOTING POWER

     

    3,498

      8  

    SHARED VOTING POWER

     

    - 0 -

      9  

    SOLE DISPOSITIVE VOTING POWER

     

    3,498

      10  

    SHARED DISPOSITIVE POWER

            

    - 0 -

    11  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,498

     
    12  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    ☐
    13  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    Less than 1%

     
    14  

    TYPE OF REPORTING PERSON

     

    OO

     

      

    4

     

     

    CUSIP No. 774374102

     

    1  

    NAME OF REPORTING PERSON

     

    The RBI Opportunities Fund, LLC

     
    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

    (a)  ☒

    (b)  ☐

    3  

    SEC USE ONLY

     

     

     
    4  

    SOURCE OF FUNDS

     

    WC

     
    5  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)

     

    ☐
    6  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    DELAWARE

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

      7  

    SOLE VOTING POWER

     

    491,700*

      8  

    SHARED VOTING POWER

     

    - 0 -

      9  

    SOLE DISPOSITIVE VOTING POWER

     

    491,700*

      10  

    SHARED DISPOSITIVE POWER

            

    - 0 -

    11  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    491,700*

     
    12  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    ☐
    13  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    5.2%*

     
    14  

    TYPE OF REPORTING PERSON

     

    OO

     

     

    *Includes 176,627 Shares issuable upon the exercise of warrants that are subject to a 19.9% blocking provision, meaning that they can be exercised only to the extent that such exercise would not cause the holder’s and its affiliates’ beneficial ownership of Shares to exceed 19.9%.

     

    Numbers reflect the reverse split that became effective on May 13, 2022.

     

    5

     

     

    CUSIP No. 774374102

     

    1  

    NAME OF REPORTING PERSON

     

    The RBI Opportunities Fund II, LLC

     
    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

    (a)  ☒

    (b)  ☐

    3  

    SEC USE ONLY

     

     

     
    4  

    SOURCE OF FUNDS

     

    WC

     
    5  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)

     

    ☐
    6  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    DELAWARE

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

      7  

    SOLE VOTING POWER

     

    205,561*

      8  

    SHARED VOTING POWER

     

    - 0 -

      9  

    SOLE DISPOSITIVE VOTING POWER

     

    205,561*

      10  

    SHARED DISPOSITIVE POWER

            

    - 0 -

    11  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    205,561*

     
    12  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    ☐
    13  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    2.2%*

     
    14  

    TYPE OF REPORTING PERSON

     

    OO

     

     

    *Includes 75,261 Shares issuable upon the exercise of warrants that are subject to a 19.9% blocking provision, meaning that they can be exercised only to the extent that such exercise would not cause the holder’s and its affiliates’ beneficial ownership of Shares to exceed 19.9%.

     

    Numbers reflect the reverse split that became effective on May 13, 2022.

     

    6

     

     

    CUSIP No. 774374102

     

    1  

    NAME OF REPORTING PERSON

     

    RBI PI Manager, LLC

     
    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

    (a)  ☒

    (b)  ☐

    3  

    SEC USE ONLY

     

     

     
    4  

    SOURCE OF FUNDS

     

    AF

     
    5  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)

     

    ☐
    6  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    DELAWARE

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

      7  

    SOLE VOTING POWER

     

    706,653*

      8  

    SHARED VOTING POWER

     

    - 0 -

      9  

    SOLE DISPOSITIVE VOTING POWER

     

    706,653*

      10  

    SHARED DISPOSITIVE POWER

            

    - 0 -

    11  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    706,653*

     
    12  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    ☐
    13  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    7.5%*

     
    14  

    TYPE OF REPORTING PERSON

     

    OO

     

     

    *Includes 251,888 Shares issuable upon the exercise of warrants that are subject to a 19.9% blocking provision, meaning that they can be exercised only to the extent that such exercise would not cause the holder’s and its affiliates’ beneficial ownership of Shares to exceed 19.9%.

     

    Numbers reflect the reverse split that became effective on May 13, 2022.

     

    7

     

     

    CUSIP No. 774374102

     

    1  

    NAME OF REPORTING PERSON

     

    Richmond Brothers 401(k) Profit Sharing Plan

     
    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

    (a)  ☒

    (b)  ☐

    3  

    SEC USE ONLY

     

     

     
    4  

    SOURCE OF FUNDS

     

    WC

     
    5  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)

     

    ☐
    6  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    MICHIGAN

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

      7  

    SOLE VOTING POWER

     

    11,360

      8  

    SHARED VOTING POWER

     

    - 0 -

      9  

    SOLE DISPOSITIVE VOTING POWER

     

    11,360

      10  

    SHARED DISPOSITIVE POWER

            

    - 0 -

    11  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    11,360

     
    12  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    ☐
    13  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    Less than 1%

     
    14  

    TYPE OF REPORTING PERSON

     

    EP

     

     

    8

     

     

    CUSIP No. 774374102

     

    1  

    NAME OF REPORTING PERSON

     

    David S. Richmond

     
    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

    (a)  ☒

    (b)  ☐

    3  

    SEC USE ONLY

     

     

     
    4  

    SOURCE OF FUNDS

     

    OO, PF

     
    5  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)

     

    ☐
    6  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    USA

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

      7   

    SOLE VOTING POWER

     

    723,357*

      8  

    SHARED VOTING POWER

     

    19,637

      9  

    SOLE DISPOSITIVE VOTING POWER

     

    723,357*

      10  

    SHARED DISPOSITIVE POWER

            

    609,142

    11  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,332,499*

     
    12  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    ☐
    13  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    14.2%*

     
    14  

    TYPE OF REPORTING PERSON

     

    IN

     

     

    *Includes 251,888 Shares issuable upon the exercise of warrants that are subject to a 19.9% blocking provision, meaning that they can be exercised only to the extent that such exercise would not cause the holder’s and its affiliates’ beneficial ownership of Shares to exceed 19.9%.

     

    Numbers reflect the reverse split that became effective on May 13, 2022.

     

    9

     

     

    CUSIP No. 774374102

     

    1  

    NAME OF REPORTING PERSON

     

    Matthew J. Curfman

     
    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

    (a)  ☒

    (b)  ☐

    3  

    SEC USE ONLY

     

     

     
    4  

    SOURCE OF FUNDS

     

    OO, PF

     
    5  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)

     

    ☐
    6  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    USA

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

      7   

    SOLE VOTING POWER

     

    4,802

      8  

    SHARED VOTING POWER

     

    20,411

      9  

    SOLE DISPOSITIVE VOTING POWER

     

    4,802

      10  

    SHARED DISPOSITIVE POWER

            

    605,781

    11  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    610,583

     
    12  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    ☐
    13  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    6.5%

     
    14  

    TYPE OF REPORTING PERSON

     

    IN

     

      

    10

     

     

    CUSIP No. 774374102

     

    The following constitutes Amendment No. 16 to the Schedule 13D filed by the undersigned (“Amendment No. 16”). This Amendment No. 16 amends the Schedule 13D as specifically set forth herein.

     

    Item 2. Identity and Background.

     

    Item 2 is hereby amended and restated to read as follows:

     

    (a) This statement is filed by:

     

      (i) Richmond Brothers, Inc., a Michigan corporation (“Richmond Brothers”), which serves as the investment advisor to certain managed accounts (the “Separately Managed Accounts”);

     

      (ii) RBI Private Investment I, LLC, a Delaware limited liability company (“RBI PI”);

     

      (iii) RBI Private Investment II, LLC, a Delaware limited liability company (“RBI PII”);

     

      (iv) The RBI Opportunities Fund, LLC, a Delaware limited liability company (“RBI Opportunities”);

     

      (v) The RBI Opportunities Fund II, LLC, a Delaware limited liability company (“RBI Opportunities II”);

     

      (vi) RBI PI Manager, LLC, a Delaware limited liability company (“RBI Manager”), which serves as the manager of RBI PI, RBI PII, RBI Opportunities and RBI Opportunities II;

     

      (vii) Richmond Brothers 401(k) Profit Sharing Plan, an employee benefit plan organized under the laws of Michigan (the “RBI Plan”);

     

      (viii) David S. Richmond, who serves as Chairman of Richmond Brothers, manager of RBI Manager and a trustee of the RBI Plan; and

     

      (ix) Matthew J. Curfman, who serves as President of Richmond Brothers and a trustee of the RBI Plan.

     

    Each of the foregoing is referred to as a “Reporting Person” and collectively as the “Reporting Persons.” Each of the Reporting Persons is party to that certain Joint Filing Agreement, as further described in Item 6. Accordingly, the Reporting Persons are hereby filing a joint Schedule 13D.

     

    (b) The address of the principal office of each of the Reporting Persons is 3568 Wildwood Avenue, Jackson, Michigan 49202.

     

    11

     

     

    CUSIP NO. 774374102

     

    (c) The principal business of Richmond Brothers is serving as a registered investment advisor and is the investment advisor to the Separately Managed Accounts. The principal business of each of RBI PI, RBI PII, RBI Opportunities and RBI Opportunities II is investing in securities. The principal business of RBI Manager is serving as the manager of RBI PI, RBI PII, RBI Opportunities and RBI Opportunities II. The principal business of the RBI Plan is investing in securities. The principal occupation of Mr. Richmond is serving as Chairman of Richmond Brothers, manager of RBI Manager and a trustee of the RBI Plan. The principal occupation of Mr. Curfman is serving as President of Richmond Brothers and a trustee of the RBI Plan.

     

    (d) No Reporting Person has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

     

    (e) No Reporting Person has, during the last five years, been party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

    (f) Messrs. Richmond and Curfman are citizens of the United States of America.

     

      Item 3. Source and Amount of Funds or Other Consideration.

     

    Item 3 is hereby amended and restated to read as follows:

     

    The Shares held in the Separately Managed Accounts and purchased by each of Richmond Brothers, RBI PI, RBI PII, RBI Opportunities, RBI Opportunities II and the RBI Plan were purchased with working capital (which may, at any given time, include margin loans made by brokerage firms in the ordinary course of business). The aggregate purchase price of the 5,570 Shares owned directly by Richmond Brothers is approximately $9,079, excluding brokerage commissions. The aggregate purchase price of the 706,653 Shares held by the Separately Managed Accounts is approximately $1,151,844, excluding brokerage commissions. The aggregate purchase price of the 5,894 Shares owned directly by RBI PI is approximately $9,607, excluding brokerage commissions. The aggregate purchase price of the 3,498 Shares owned directly by RBI PII is approximately $5,702, excluding brokerage commissions. The aggregate purchase price of the 697,261 Shares (together with the warrants referenced in the first sentence of the following paragraph) owned in the aggregate by RBI Opportunities and RBI Opportunities II is $1,136,535, excluding brokerage commissions. The aggregate purchase price of the 11,360 Shares owned directly by the RBI Plan is approximately $18,517, excluding brokerage commissions.

     

    Pursuant to the Securities Purchase Agreement entered into on October 15, 2018 (as defined and described in Amendment No. 12 to the Schedule 13D), RBI Opportunities received warrants exercisable into 251,888 Shares from the Issuer, of which warrants exercisable into 75,261 Shares were transferred to RBI Opportunities II in an exempt transaction. The warrants have an exercise price of $54.56 per Share and will now expire on April 30, 2025.

     

    The Shares purchased by Mr. Richmond were purchased with personal funds (which may, at any given time, include margin loans made by brokerage firms in the ordinary course of business). The aggregate purchase price of the 19,411 Shares beneficially owned by Mr. Richmond, including 2,707 Shares directly owned by his spouse and 4,135 Shares directly owned by his daughter, is approximately $31,639, excluding brokerage commissions.

     

    The Shares purchased by Mr. Curfman were purchased with personal funds (which may, at any given time, include margin loans made by brokerage firms in the ordinary course of business). The aggregate purchase price of the 4,802 Shares beneficially owned by Mr. Curfman, including the 3,481 Shares directly owned by his spouse, is approximately $7,827, excluding brokerage commissions.

     

    12

     

     

    CUSIP No. 774374102

     

    Item 5. Interest in Securities of the Issuer.

     

    Items 5 to Schedule 13D is hereby amended and restated, in pertinent part, as follows:

     

    The aggregate percentage of Shares reported owned by each person named herein is based upon 9,384,591 Shares outstanding as of May 30, 2022, which is the total number of Shares outstanding based on information contained in the Issuer’s Prospectus Supplement filed pursuant to Rule 424(b)(5) with the Securities and Exchange Commission on June 1, 2022. The Reporting Persons beneficially own those Shares as follows

     

    A. Richmond Brothers

     

      (a) As of the date hereof, Richmond Brothers directly beneficially owned 5,570 Shares, and an additional 595,505 Shares were held in the Separately Managed Accounts. As the investment advisor to the Separately Managed Accounts, Richmond Brothers may also be deemed the beneficial owner of the 595,505 Shares held in the Separately Managed Accounts.

    Percentage: Approximately 6.3%

     

      (b) 1. Sole power to vote or direct vote: 5,570
    2. Shared power to vote or direct vote: 0
    3. Sole power to dispose or direct the disposition: 5,570
    4. Shared power to dispose or direct the disposition: 589,505

     

    B. RBI PI

     

      (a) As of the date hereof, RBI PI beneficially owned 5,894 Shares.

    Percentage: Less than 1%

     

      (b) 1. Sole power to vote or direct vote: 5,894
    2. Shared power to vote or direct vote: 0
    3. Sole power to dispose or direct the disposition: 5,894
    4. Shared power to dispose or direct the disposition: 0

     

    13

     

     

    CUSIP No. 774374102

     

    C. RBI PII

     

      (a) As of the date hereof, RBI PII beneficially owned 3,498 Shares.

    Percentage: Less than 1%

     

      (b) 1. Sole power to vote or direct vote: 3,498
    2. Shared power to vote or direct vote: 0
    3. Sole power to dispose or direct the disposition: 3,498
    4. Shared power to dispose or direct the disposition: 0

     

    D. RBI Opportunities

     

      (a) As of the date hereof, RBI Opportunities beneficially owned 491,700 Shares (including 176,627 Shares issuable upon the exercise of warrants that are subject to a 19.9% blocking provision, meaning that they can be exercised only to the extent that such exercise would not cause the holder’s and its affiliates’ beneficial ownership of Shares to exceed 19.9% of the outstanding Shares).

    Percentage: Approximately 5.2%

     

      (b) 1. Sole power to vote or direct vote: 491,700
    2. Shared power to vote or direct vote: 0
    3. Sole power to dispose or direct the disposition: 491,700
    4. Shared power to dispose or direct the disposition: 0

     

    E. RBI Opportunities II

     

      (a) As of the date hereof, RBI Opportunities II beneficially owned 205,561 Shares (including 75,261 Shares issuable upon the exercise of warrants that are subject to a 19.9% blocking provision, meaning that they can be exercised only to the extent that such exercise would not cause the holder’s and its affiliates’ beneficial ownership of Shares to exceed 19.9% of the outstanding Shares).

    Percentage: Approximately 2.2%

     

      (b) 1. Sole power to vote or direct vote: 205,561
    2. Shared power to vote or direct vote: 0
    3. Sole power to dispose or direct the disposition: 205,561
    4. Shared power to dispose or direct the disposition: 0

     

    14

     

     

    CUSIP No. 774374102

     

    F. RBI Manager

     

      (a) As the manager of RBI PI, RBI PII, RBI Opportunities and RBI Opportunities II, RBI Manager may be deemed the beneficial owner of the (i) 5,894 Shares owned by RBI PI, (ii) 3,498 Shares owned by RBI PII, (iii) 491,700 Shares beneficially owned by RBI Opportunities and (iv) 205,561 Shares beneficially owned by RBI Opportunities II.

    Percentage: Approximately 7.5%

     

      (b) 1. Sole power to vote or direct vote: 706,653
    2. Shared power to vote or direct vote: 0
    3. Sole power to dispose or direct the disposition: 706,653
    4. Shared power to dispose or direct the disposition: 7.5%

     

    G. RBI Plan

     

      (a) As of the date hereof, the RBI Plan beneficially owned 11,360 Shares.

    Percentage: Less than 1%

     

      (b) 1. Sole power to vote or direct vote: 11,360
    2. Shared power to vote or direct vote: 0
    3. Sole power to dispose or direct the disposition: 11,360
    4. Shared power to dispose or direct the disposition: 0

     

    H. Mr. Richmond

     

      (a) As of the date hereof, Mr. Richmond beneficially owned 723,357 Shares, including 2,707 Shares directly owned by his spouse, 4,135 Shares directly owned by his daughter. As the Chairman of Richmond Brothers, manager of RBI Manager and a trustee of the RBI Plan, Mr. Richmond may also be deemed the beneficial owner of the (i) 5,570 Shares owned directly by Richmond Brothers, (ii) 595,505 Shares held in the Separately Managed Accounts, (iii) 5,894  Shares owned by RBI PI, (iv) 38,490 Shares owned by RBI PII, (v) 491,700 Shares beneficially owned by RBI Opportunities, (vi) 205,561 Shares beneficially owned by RBI Opportunities II and (vii) 11,360 Shares owned by the RBI Plan.

    Percentage: Approximately 14.2%

     

      (b) 1. Sole power to vote or direct vote: 723,357
    2. Shared power to vote or direct vote: 19,637
    3. Sole power to dispose or direct the disposition: 723,357
    4. Shared power to dispose or direct the disposition: 609,142

     

    15

     

     

    CUSIP No. 774374102

     

    I. Mr. Curfman

     

      (a) As of the date hereof, Mr. Curfman beneficially owned 4,802 Shares, including 3,481 Shares directly owned by his spouse. As the President of Richmond Brothers and a trustee of the RBI Plan, Mr. Curfman may also be deemed the beneficial owner of the (i) 5,570 Shares owned directly by Richmond Brothers, (ii) 595,505 Shares held in the Separately Managed Accounts and (iii) 11,360 Shares owned by the RBI Plan.

    Percentage: Approximately 6.5%

     

      (b) 1. Sole power to vote or direct vote: 4,802
    2. Shared power to vote or direct vote: 20,411
    3. Sole power to dispose or direct the disposition: 4,802
    4. Shared power to dispose or direct the disposition: 605,781

     

    An aggregate of 1,332,499 Shares (including 251,888 Shares issuable upon the exercise of warrants that are subject to a 19.9% blocking provision), constituting beneficial ownership of approximately 14.2% of the outstanding Shares, are reported in this Amendment No. 16 to the Schedule 13D.

     

    The filing of this Schedule 13D shall not be deemed an admission that the Reporting Persons are, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, the beneficial owners of any Shares he or it does not directly own. Each of the Reporting Persons specifically disclaims beneficial ownership of the Shares reported herein that he or it does not directly own.

     

      (c) The transactions in the securities of the Issuer by the Reporting Persons during the past sixty days are set forth in Schedule A and are incorporated herein by reference. Such transactions were effected in the open market.

     

    16

     

     

    CUSIP No. 774374102

     

    SIGNATURES

     

    After reasonable inquiry and to the best of his knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Dated: June 23, 2022

     

      Richmond Brothers, Inc.
         
      By:  /s/ David S. Richmond
        Name:   David S. Richmond
        Title: Chairman

     

      RBI Private Investment I, LLC
       
      By: RBI PI Manager, LLC
        Manager
         
      By:  /s/ David S. Richmond
        Name:   David S. Richmond
        Title: Manager

     

      RBI Private Investment II, LLC
       
      By: RBI PI Manager, LLC
        Manager
         
      By:  /s/ David S. Richmond
        Name:   David S. Richmond
        Title: Manager

     

      The RBI Opportunities Fund, LLC
       
      By: RBI PI Manager, LLC
        Manager
         
      By:  /s/ David S. Richmond
        Name:   David S. Richmond
        Title: Manager

     

    17

     

     

    CUSIP No. 774374102

     

      The RBI Opportunities Fund II, LLC
       
      By: RBI PI Manager, LLC
        Manager
         
      By:  /s/ David S. Richmond
        Name:   David S. Richmond
        Title: Manager

     

      By: RBI PI Manager, LLC
         
      By:  /s/ David S. Richmond
        Name:   David S. Richmond
        Title: Manager

     

      By: Richmond Brothers 401(k) Profit Sharing Plan
         
      By:  /s/ David S. Richmond
        Name:   David S. Richmond
        Title: Trustee

     

       /s/ David S. Richmond
      David S. Richmond
       
       /s/ Matthew J. Curfman
      Matthew J. Curfman

     

    18

     

     

    CUSIP No. 774374102

     

    SCHEDULE A

     

    Transactions in the Securities of the Issuer During the past sixty days

     

    Nature of Transaction  Securities
    Purchased/(Sold)
       Price per Security ($)   Date of
    Purchase / Sale
       Richmond Brothers, Inc.
    (Through the Separately Managed Accounts)
        
    Sale of Common Stock   (2,631)   0.2850   05/10/2022
    Sale of Common Stock   (2,348)   0.2850   05/10/2022
    Sale of Common Stock   (125)   1.9457   05/17/2022
    Sale of Common Stock   (202)   1.9601   05/18/2022
    Sale of Common Stock   (339)   1.9250   05/19/2022
    Sale of Common Stock   (304)   1.6700   06/02/2022
    Sale of Common Stock   (303)   1.6750   06/02/2022
    Sale of Common Stock   (757)   1.5165   06/08/2022
    Sale of Common Stock   (84)   1.5050   06/09/2022
    Sale of Common Stock   (1,157)   1.4200   06/10/2022
    Sale of Common Stock   (787)   1.4077   06/10/2022
    Sale of Common Stock   (751)   1.3200   06/14/2022
    Sale of Common Stock   (20)   1.3400   06/14/2022
    Sale of Common Stock   (388)   1.3265   06/14/2022
    Sale of Common Stock   (101)   1.4170   06/17/2022
    Sale of Common Stock   (102)   1.4206   06/17/2022
    Sale of Common Stock   (67)   1.3997   06/17/2022
    Sale of Common Stock   (52)   1.4077   06/17/2022
    Sale of Common Stock   (92)   1.3989   06/17/2022

     

     

     

     19

     

    Get the next $RMTI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RMTI

    DatePrice TargetRatingAnalyst
    11/14/2024$5.00Buy
    Rodman & Renshaw
    1/18/2022$5.00 → $3.00Buy
    HC Wainwright & Co.
    9/7/2021$5.50 → $5.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $RMTI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Rockwell Medical Announces First Quarter 2025 Results

      Reports net sales of $18.9 million for the first quarter of 2025, a 17% decrease from net sales of $22.7 million for the first quarter of 2024. Reports gross profit of $3.0 million for the first quarter of 2025, in line with the same period in 2024. Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced financial and operational results for the three months ended March 31, 2025. "During the first quarter, we continued to diversify our customer base with some of the leading regional, national and global hemodialysis provi

      5/12/25 6:00:00 AM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rockwell Medical to Release First Quarter 2025 Results on Monday, May 12, 2025

      Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it will release its financial and operational results for the first quarter ended March 31, 2025 on Monday, May 12, 2025. The Company will issue a press release at 6:00am ET followed by a live conference call and webcast at 8:00am ET. CONFERENCE CALL AND WEBCAST DETAILS Date: Monday, May 12, 2025 Time: 8:00am ET Live Number: (888) 660-6347 // (International) 1 (929) 201-6594 Conference Call ID: 4944610 Webcast and Replay: www.RockwellMed.com/Results Speakers:

      4/14/25 6:00:00 AM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rockwell Medical Announces Fourth Quarter and Full-Year 2024 Financial and Operational Results

      Achieves profitability on an adjusted EBITDA basis for the full-year 2024, the first time in the Company's history. Reports record gross profit for the third year in a row, generating $17.5 million in 2024, a 101% increase over 2023. Reports record net sales for the third year in a row, generating $101.5 million in 2024, a 21% increase over 2023. Net sales for the fourth quarter of 2024 were $24.7 million, a 12% increase over the same period in 2023. Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced financial and o

      3/20/25 6:00:00 AM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RMTI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Rodman & Renshaw initiated coverage on Rockwell Medical with a new price target

      Rodman & Renshaw initiated coverage of Rockwell Medical with a rating of Buy and set a new price target of $5.00

      11/14/24 7:56:29 AM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Rockwell Medical with a new price target

      HC Wainwright & Co. reiterated coverage of Rockwell Medical with a rating of Buy and set a new price target of $3.00 from $5.00 previously

      1/18/22 10:00:06 AM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Rockwell Medical with a new price target

      HC Wainwright & Co. reiterated coverage of Rockwell Medical with a rating of Buy and set a new price target of $5.00 from $5.50 previously

      9/7/21 6:17:47 AM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RMTI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Irrevocable Larson Family Investment Trust bought $94,018 worth of shares (87,500 units at $1.07), increasing direct ownership by 3% to 3,557,500 units (SEC Form 4)

      4 - ROCKWELL MEDICAL, INC. (0001041024) (Issuer)

      4/15/25 2:02:44 PM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Strobeck Mark sold $7,480 worth of shares (6,926 units at $1.08), decreasing direct ownership by 5% to 124,678 units (SEC Form 4)

      4 - ROCKWELL MEDICAL, INC. (0001041024) (Issuer)

      4/2/25 6:06:41 PM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVP, FINANCE AND CFO Neri Jesse sold $975 worth of shares (886 units at $1.10), decreasing direct ownership by 3% to 30,000 units (SEC Form 4)

      4 - ROCKWELL MEDICAL, INC. (0001041024) (Issuer)

      4/2/25 6:05:02 PM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RMTI
    SEC Filings

    See more

    $RMTI
    Leadership Updates

    Live Leadership Updates

    See more

    $RMTI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Rockwell Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - ROCKWELL MEDICAL, INC. (0001041024) (Filer)

      5/12/25 7:21:47 AM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Rockwell Medical Inc.

      10-Q - ROCKWELL MEDICAL, INC. (0001041024) (Filer)

      5/12/25 7:00:44 AM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rockwell Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ROCKWELL MEDICAL, INC. (0001041024) (Filer)

      5/12/25 6:18:10 AM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Universal Display Corporation Announces the Appointment of New Board Members

      Universal Display Corporation (NASDAQ:OLED) (UDC), enabling energy-efficient displays and lighting with its UniversalPHOLED® technology and materials, today announced that Dr. Nigel Brown and Dr. Joan Lau have joined the Company's Board of Directors, effective March 4, 2024. The addition of these new directors expands UDC's Board to ten members. "I am pleased to welcome Nigel and Joan to the Board," said Steven V. Abramson, President and Chief Executive Officer of Universal Display Corporation and a member of the Board. "Nigel adds a wealth of business innovation, technical knowledge and corporate strategic planning expertise to our Board. Joan brings over two decades of extensive scienti

      3/7/24 4:05:00 PM ET
      $BDN
      $NOTV
      $OLED
      $RMTI
      Real Estate Investment Trusts
      Real Estate
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Rockwell Medical Appoints Joan Lau, Ph.D. to the Company's Board of Directors

      Brings more than 20 years of experience as an entrepreneur scientist, CEO, operator, investor, and board member of public and private biopharmaceutical companies Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company appointed Joan Lau, Ph.D. to its board of directors. Dr. Lau's appointment increases Rockwell Medical's board of directors to seven members. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231017906241/en/RMTI) (Photo: Business Wire)"

      10/17/23 6:00:00 AM ET
      $BDN
      $RMTI
      $RCOR
      Real Estate Investment Trusts
      Real Estate
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rockwell Medical, Inc. Appoints Mark Strobeck, Ph.D., as President and Chief Executive Officer

      WIXOM, Mich. , June 22, 2022 /PRNewswire/ -- Rockwell Medical, Inc. (NASDAQ:RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management, today announced that the Board of Directors has appointed Mark Strobeck, Ph.D., as President and Chief Executive Officer, effective July 1, 2022. Dr. Strobeck will also join the Company's Board of Directors. Russell Ellison, M.D., M.Sc., will be stepping down as President and Chief Executive Officer and as a member of the Company's Board of Directors effective June 30, 2022. "We are exci

      6/24/22 8:56:00 AM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Irrevocable Larson Family Investment Trust bought $94,018 worth of shares (87,500 units at $1.07), increasing direct ownership by 3% to 3,557,500 units (SEC Form 4)

      4 - ROCKWELL MEDICAL, INC. (0001041024) (Issuer)

      4/15/25 2:02:44 PM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RMTI
    Financials

    Live finance-specific insights

    See more
    • Rockwell Medical Announces First Quarter 2025 Results

      Reports net sales of $18.9 million for the first quarter of 2025, a 17% decrease from net sales of $22.7 million for the first quarter of 2024. Reports gross profit of $3.0 million for the first quarter of 2025, in line with the same period in 2024. Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced financial and operational results for the three months ended March 31, 2025. "During the first quarter, we continued to diversify our customer base with some of the leading regional, national and global hemodialysis provi

      5/12/25 6:00:00 AM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rockwell Medical to Release First Quarter 2025 Results on Monday, May 12, 2025

      Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it will release its financial and operational results for the first quarter ended March 31, 2025 on Monday, May 12, 2025. The Company will issue a press release at 6:00am ET followed by a live conference call and webcast at 8:00am ET. CONFERENCE CALL AND WEBCAST DETAILS Date: Monday, May 12, 2025 Time: 8:00am ET Live Number: (888) 660-6347 // (International) 1 (929) 201-6594 Conference Call ID: 4944610 Webcast and Replay: www.RockwellMed.com/Results Speakers:

      4/14/25 6:00:00 AM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rockwell Medical Announces Fourth Quarter and Full-Year 2024 Financial and Operational Results

      Achieves profitability on an adjusted EBITDA basis for the full-year 2024, the first time in the Company's history. Reports record gross profit for the third year in a row, generating $17.5 million in 2024, a 101% increase over 2023. Reports record net sales for the third year in a row, generating $101.5 million in 2024, a 21% increase over 2023. Net sales for the fourth quarter of 2024 were $24.7 million, a 12% increase over the same period in 2023. Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced financial and o

      3/20/25 6:00:00 AM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RMTI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Rockwell Medical Inc.

      SC 13G/A - ROCKWELL MEDICAL, INC. (0001041024) (Subject)

      11/14/24 5:17:40 PM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Rockwell Medical Inc. (Amendment)

      SC 13G/A - ROCKWELL MEDICAL, INC. (0001041024) (Subject)

      2/14/24 2:31:02 PM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Rockwell Medical Inc. (Amendment)

      SC 13D/A - ROCKWELL MEDICAL, INC. (0001041024) (Subject)

      9/6/23 4:49:44 PM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care